Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients in Real World Setting

Primary outcomes

• Prevalence of tissue HRR-related gene mutations [Baseline]: Calculate number and prevalence of each HRR-related gene mutation status (Positive/Negative/VUS), respectively. Prevalence will be accompanied by 95% Clopper-Pearson confidence intervals.

Secondary outcomes

• Proportion of each treatment pattern [From index date(diagnosed as mCRPC) patients to December 31 2020]: The number (%) of patients by treatment pattern in 1st line treatment, 2nd line, and 3rd line treatment after diagnosed as mCRPC, respectively, will be calculated.

Other outcomes

• Patient's characteristics including stratified by tissue HRR-related gene mutations in mCRPC patients [Baseline]: Patient's characteristics will be summarized.
• PSA50 response [From index date(diagnosed as mCRPC) to december 31 2020]: PSA50 response will be analysed based on baseline and nadir PSA value in each treatment.

Sex: Male

Inclusion Criteria:

* Age > 20, Japanese men at the time of informed consent.
* Patients who provided informed consent. If the patient has died, opt-out will be applicable.
* Patients who are diagnosed as mCRPC between January 1st in 2014 and December 31st in 2018.
* Patients who have a FFPE tumor sample (primary or metastatic) with Formalin Neutral Buffer Solution.
* Patients which the investigator judges to secure the enough amount of tumor samples for future laboratory test.

Exclusion Criteria:

* Patients who have failed HRR-related gene mutation testing with the myChoice HRD plus in screening period.
* Patients who have an only FFPE primary tumor sample (primary or metastatic) with unbuffered formalin including acidic formalin.
* Patients who have taken an investigational medical product for prostate cancer from Jan 1st , 2014 to Dec 31st 2020.